Berberine improves ovulation and endometrial receptivity in polycystic ovary syndrome

Wang, Zhi; Nie, Kexin; Su, Hao; Tang, Yueheng; Wang, Hongzhan; Xu, Xiaohu

doi:10.1016/j.phymed.2021.153654

Cited by 31 publications

(30 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are in congruence with the results obtained in our study. This improvement in reproductive hormones and metabolic parameters is explained by increased sensitivity to insulin and steroid hormone synthesis after berberine treatment, as demonstrated in other studies [14]. However, this study showed a significant improvement in WHR with no effect on BMI and WC with berberine compared to placebo/no treatment [13].…”

Section: Discussionsupporting

confidence: 75%

Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study

Mishra¹,

Verma²,

Jadaun³

2022

Cureus

View full text Add to dashboard Cite

Objective: This study was conducted to see the effects of berberine, metformin, and myoinositol in women with polycystic ovary syndrome (PCOS).Materials and Methods: Subjects were randomly assigned via computer-generated randomization to one of the three treatment groups. Group 1 received berberine hydrochloride 500 mg twice daily, group 2 received metformin hydrochloride 500 mg twice daily, and group 3 received myoinositol 1000 mg twice daily to compare clinically (mean weight, waist circumference, waist-to-hip ratio, and body mass index), metabolic (fasting blood sugar, serum fasting insulin, fasting blood sugar/serum fasting insulin [FBS/FI]), hormonal effects (serum total testosterone [TT], serum sex hormone-binding globulin [SHBG] and free androgen index) together with the lipid profile (total cholesterol, serum triglyceride, serum low-density lipoprotein [LDL], very-low-density lipoprotein [VLDL], serum high-density lipoprotein [HDL]) in patients receiving metformin, berberine, and myoinositol before and after three months of treatment.Results: Weight, BMI, waist circumference, waist-hip ratio, FBS, FI and fasting glucose/insulin ratio, total testosterone, free androgen index (FAI), SHBG, total cholesterol, triglycerides, LDL, VLDL, and HDL showed significant differences in three groups after three months of treatment (p<0.0001). Between the three groups, berberine showed greater differences in clinical, hormonal, and lipid parameters compared to metformin and myoinositol, while myoinositol showed greater improvement in carbohydrate metabolic parameters.Conclusions: Metformin, the classical drug used in PCOS, improves all the parameters in polycystic ovary syndrome women. Berberine may have greater potential to reduce the risk of cardiovascular disease than metformin in PCOS patients due to its effect on body composition, lipid profile, and improvement in hormone status. Myoinositol administration improves endocrine parameters and insulin sensitivity. It may be considered as a first-line option in PCOS patients with insulin resistance without prediabetes or diabetes.

show abstract

Section: Discussionsupporting

confidence: 75%

Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study

Mishra¹,

Verma²,

Jadaun³

2022

Cureus

View full text Add to dashboard Cite

show abstract

“…The use of berberine decreased the concentration of LH, total cholesterol, and improved glucose tolerance without affecting the fasting insulin concentration. Moreover, higher expression of LHCGR and CYP19A1 proteins was investigated in ovarian granular cells, which may have a positive effect on ovulation [10]. Another study looked at the effects of berberine on the menstrual cycle, ovulation rate, and hormone profile in non-ovulating Chinese women with PCOS.…”

Section: Resultsmentioning

confidence: 99%

Berberine in the treatment of polycystic ovary syndrome

Ochyra

Łopuszyńska

Pawlicki

et al. 2022

J Educ Health Sport

View full text Add to dashboard Cite

Introduction: Polycystic ovary syndrome (PCOS) is a hormonal disorder most common in women in reproductive age. The global incidence varies from 6% to 20% depending on the diagnostic criteria used, and is also the most common cause of infertility. This disease is related to insulin resistance and hyperinsulinemia. Berberine is a compound that affects the cardiovascular system and carbohydrate metabolism, which is why there are attempts to introduce it into the therapy of patients with PCOS. Material and methods: The literature was reviewed in the PubMed scientific base in the years 2012-2022 using the following keywords: berberine, polycystic ovary syndrome. Results: Research show that the use of berberine may have a positive effect on the waist circumference and waist-to-hip ratio, improve lipid parameters, lower the concentration of androgens, and reduce insulin resistance. In addition, a promising effect is the stabilization of the menstrual cycle and improvement of ovulation. There are reports that this drug may also restore the normal composition of the intestinal microflora disrupted in PCOS. Side effects are rare and mild, which confirms the safety of this substance. Conclusions: Polycystic ovary syndrome affects many women, leading to numerous and serious side effects, so it is important to develop an effective treatment with as few side effects as possible. Berberine is a promising prospect, but more studies are needed on larger groups of patients to confirm these reports and develop an effective treatment regimen. Keywords: berberine, polycystic ovary syndrome.

show abstract

“…Polycystic ovary syndrome (PCOS) is a clinical disease characterized by reproductive and endocrine abnormalities and affects 5-10% of females of childbearing age. PCOS is linked to luteinizing hormone hypersecretion, hyperinsulinemia, hyperandrogenemia, hirsutism, menstrual dysfunction, infertility, and pregnancy and neonatal problems [66,67]. The ovaries of a female with PCOS are largely affected by the elevated levels of insulin, as it leads to increased production of androgen hormones such as testosterone.…”

Section: Polycystic Ovary Syndromementioning

confidence: 99%

Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends

et al. 2022

View full text Add to dashboard Cite

Traditionally, herbal compounds have been the focus of scientific interest for the last several centuries, and continuous research into their medicinal potential is underway. Berberine (BBR) is an isoquinoline alkaloid extracted from plants that possess a broad array of medicinal properties, including anti-diarrheal, anti-fibrotic, antidiabetic, anti-inflammatory, anti-obesity, antihyperlipidemic, antihypertensive, antiarrhythmic, antidepressant, and anxiolytic effects, and is frequently utilized as a traditional Chinese medicine. BBR promotes metabolisms of glucose and lipids by activating adenosine monophosphate-activated protein kinase, stimulating glycolysis and inhibiting functions of mitochondria; all of these ameliorate type 2 diabetes mellitus. BBR has also been shown to have benefits in congestive heart failure, hypercholesterolemia, atherosclerosis, non-alcoholic fatty liver disease, Alzheimer’s disease, and polycystic ovary syndrome. BBR has been investigated as an interesting pharmacophore with the potential to contribute significantly to the research and development of novel therapeutic medicines for a variety of disorders. Despite its enormous therapeutic promise, the clinical application of this alkaloid was severely limited because of its unpleasant pharmacokinetic characteristics. Poor bioavailability, limited absorption, and poor water solubility are some of the obstacles that restricted its use. Nanotechnology has been suggested as a possible solution to these problems. The present review aims at recent updates on important therapeutic activities of BBR and different types of nanocarriers used for the delivery of BBR in different diseases.

show abstract

Berberine improves ovulation and endometrial receptivity in polycystic ovary syndrome

Cited by 31 publications

References 28 publications

Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study

Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study

Berberine in the treatment of polycystic ovary syndrome

Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends

Contact Info

Product

Resources

About